Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 12/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.48 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7212785 | 0.82 | PTGS2 (0.47) | CA2CA9CA1CA12PTGS2 | |
| SCHEMBL6151087 | 0.80 | CA2 (0.48) | CA2CA9CA1CA12PTGS2 | |
| SCHEMBL27467613 | 0.79 | CA2 (0.47) | CA2CA9CA1CA12PTGS2 | |
| SCHEMBL7637660 | 0.79 | CA2 (0.54) | CA2CA9CA1CA12PTGS2 | |
| SCHEMBL6792751 | 0.76 | PTGS2 (0.58) | CA2CA9CA1CA12PTGS2 | |
| SCHEMBL8474212 | 0.72 | PTGS2 (0.57) | CA2CA9CA1CA12PTGS2 | |
| SCHEMBL6151278 | 0.70 | PTGS2 (0.47) | CA2CA9CA1CA12PTGS2 | |
| SCHEMBL8478863 | 0.70 | PTGS2 (0.54) | CA2CA9CA1CA12PTGS2 | |
| SCHEMBL3879530 | 0.70 | CA2 (0.66) | CA2CA9CA1CA12PTGS2 | |
| SCHEMBL6728102 | 0.69 | PTGS2 (0.67) | CA2CA9CA1CA12PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6458805-B2 | ANTAGONISTS; ESPECIALLY SODIUM SALTS | TEXAS BIOTECHNOLOGY CORPORATION | 2002-10-01 | — | — | US | disclosed |
| US-20010039289-A1 | Formulation of sulfonamides for treatment of endothelin-mediated disorders | ENCYSIVE PHARMACEUTICALS INC. | 2001-11-08 | — | — | US | disclosed |
| US-6248767-B1 | VASOCONSTRICTION | TEXAS BIOTECHNOLOGY CORP. | 2001-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039289-A1 | Formulation of sulfonamides for treatment of endothelin-mediated disorders | EDNRA, EDNRB, ECE1 | CA2 760/4885CA9 2262/4885CA1 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.